Literature DB >> 3883934

Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients.

J P Bantle, K A Nath, D E Sutherland, J S Najarian, T F Ferris.   

Abstract

To evaluate the mechanism of cyclosporine-induced hyperkalemia, the renin-angiotensin-aldosterone system and renal potassium clearance were compared in ten renal transplant recipients treated with cyclosporine and treated with azathioprine. After stimulation by a low-sodium diet and furosemide, cyclosporine-treated patients demonstrated lower plasma renin activity when supine (1.9 +/- 0.3 v 7.8 +/- 1.4 ng/mL/hr) and after standing (3.0 +/- 0.7 v 12.2 +/- 1.5 ng/mL/hr). Supine plasma aldosterone levels tended to be lower in cyclosporine-treated patients, (4.8 +/- v 10.5 +/- 2.6 ng/dL), although standing plasma aldosterone levels were not different (10.8 +/- 3.0 v 12.3 +/- 2.0 ng/dL). After administration of 0.75 mEq of potassium chloride per kilogram of body weight, cyclosporine-treated patients excreted 52% +/- 7.1% of the potassium load in six hours compared with excretion of 67% +/- 7.0% by the azathioprine-treated patients, although there was no difference in plasma aldosterone levels in response to the potassium load in the two groups. These data suggest that cyclosporine causes suppression of plasma renin activity and a tubular insensitivity to aldosterone, both of which may impair potassium excretion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3883934

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  18 in total

Review 1.  Cardiac transplantation. Selection, immunosuppression, and survival.

Authors:  L W Stevenson; H Laks; P I Terasaki; B D Kahan; D C Drinkwater
Journal:  West J Med       Date:  1988-11

Review 2.  Complications of cyclosporin therapy.

Authors:  B D Kahan; S M Flechner; M I Lorber; C Jensen; D Golden; C T Van Buren
Journal:  World J Surg       Date:  1986-06       Impact factor: 3.352

Review 3.  Primary care of the renal transplant patient.

Authors:  J D Pirsch; R Friedman
Journal:  J Gen Intern Med       Date:  1994-01       Impact factor: 5.128

Review 4.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

5.  Isolated hyperkalemia associated with cyclosporine administration in allogeneic stem cell transplantation for renal cell carcinoma.

Authors:  Akiyoshi Takami; Hidesaku Asakura; Hiroyuki Takamatsu; Hirohito Yamazaki; Masahisa Arahata; Tomoe Hayashi; Masami Shibayama; Michiko Orito; Tomotaka Yoshida; Mikio Namiki; Shinji Nakao
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

6.  Cyclosporin A-induced nephrotoxicity in the rat: relationship to increased plasma renin activity.

Authors:  F T McAuley; J G Simpson; A W Thomson; P H Whiting
Journal:  Agents Actions       Date:  1987-06

Review 7.  The problems and pitfalls of NSAID therapy in the elderly (Part II).

Authors:  A G Johnson; R O Day
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

8.  Functional effects on glomerular hemodynamics of short-term chronic cyclosporine in male rats.

Authors:  S C Thomson; B J Tucker; F Gabbai; R C Blantz
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

9.  Differential diagnosis of hyperkalemia: an update to a complex problem.

Authors:  T Eleftheriadis; K Leivaditis; G Antoniadi; V Liakopoulos
Journal:  Hippokratia       Date:  2012-10       Impact factor: 0.471

Review 10.  Cardiovascular disease in transplant recipients: current and future treatment strategies.

Authors:  John S Gill
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.